October 13, 2022 —Kindeva Drug Delivery LP (Kindeva) has announced a collaboration with the Temple University School of Pharmacy to provide liquid intradermal transdermal system units for the evaluation of nanoparticle-based approaches to overcome tumor drug resistance in rodent models.

Jayanth Panyam, professor of pharmaceutical sciences and dean of the Temple University School of Pharmacy, was awarded a five-year National Institute of Health grant in 2021 to evaluate TLR7/8 agonist based nanovaccines in rodent models. For this grant, Panyam’s research will evaluate nanoparticle biodistribution following intradermal delivery compared to conventional subcutaneous delivery, evaluate in vivo humoral, Th1/Th2 and cytotoxic immune responses, and evaluate in vivo efficacy in rat mammary tumor models. Kindeva will provide Panyam liquid intradermal units for intradermal administration.

“We are very excited for the opportunity to partner with Panyam on this project. Kindeva is excited that our liquid intradermal technology was selected in part due to its ability to consistently deliver a solution intradermally. The high-quality manufacturing techniques used in creating our microneedle array will help ensure that we reach the correct level within the skin time and time again,” said John Vasilakos, global head of MTS business development and senior research immunologist.

“Kindeva’s liquid intradermal system will allow us to deliver our novel nanovaccine formulations intradermally in a consistent and reproducible format, which is expected to significantly improve anticancer immune response with these formulations,” added Panyam.

About Kindeva Drug Delivery

Headquartered in Woodbury, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization in the pharmaceutical industry, with major R&D and manufacturing sites in the U.K. at Loughborough and Clitheroe. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microneedle transdermal systems and connected drug delivery. Kindeva employs approximately 1,000 people worldwide. kindevadd.com.

About the Temple University School of Pharmacy

The Temple University School of Pharmacy, established in 1901, carries more than a century’s worth of history and reliability in pharmacy education. Our programs, assets and products support our ongoing success in creating opportunities to transform lives. The school provides opportunities to earn degrees in pharmacy, pharmaceutical sciences, and regulatory affairs and

quality assurance and lead innovations in pharmacy practice and science. We promote and preserve pharmacy and pharmacy-related professions by delivering excellence and opportunity through education, scholarship, research and practice.